Effects of Propranolol on the Encoding and Retrieval of Emotional Material After Single Dose Administration in Healthy Young Subjects

Inclusion Criteria: * age: 18 - 35 years * sex: male * ethnic origin: Caucasian * body weight: between 19 kg/m² and 27 kg/m² \[calculated from weight (kg)/height2 (m2)\] * good health as evidenced by the results of the clinical examination, ECG, and laboratory check-up, which are judged by the clinical investigator not to differ in a clinical relevant way from the normal state * written informed consent Exclusion Criteria: * obstructive lung disease (e.g. bronchial asthma) * peripheral arterial circulatory disturbance * any disturbance of impulse formation and conduction (e.g. sick sinus syndrome, SA or AV-blockade) * bradycardia (\< 50 beats/min) * hypotension (systolic pressure \< 90 mmHg) * existing cardiac or hematological diseases and/or pathological findings, which might interfere with the drug's safety, tolerability, absorption and/or pharmacokinetics * existing hepatic and renal diseases and/or pathological findings, which might interfere with the drug's safety, tolerability, absorption and/or pharmacokinetics * existing gastrointestinal diseases and/or pathological findings, which might interfere with the drug's safety, tolerability, absorption and/or pharmacokinetics * existing or further diseases of the CNS, especially epilepsy * acute or chronic diseases which could affect absorption or metabolism * history of any serious psychological disorder * taking MAO inhibitors * drug or alcohol dependence * positive drug or alcohol screening * smokers * positive anti-HIV-test, HBs-Ag-test or anti-HCV-test * volunteers who are on a diet which could affect the pharmacokinetics of the drug * heavy tea or coffee drinkers (more than 1L per day) * volunteers suspected or known not to follow instructions * volunteers working night shifts * volunteers who are in stressful periods or had undergone major life changes (e.g. death of a close family member in the past year) * volunteers who are unable to understand the written and verbal instructions, in particular regarding the risks and inconveniences they will be exposed to as a result of their participation in the study * participation in another clinical trial during this study * less than 14 days after last acute disease * any systemically available medication within 4 weeks prior to the intended first administration unless because of the terminal elimination half-life complete elimination from the body can be assumed for the drug and/or its primary metabolites * repeated use of drugs during the last 4 weeks prior to the intended first administration, which can influence hepatic biotransformation (e.g. barbiturates, cimetidine, phenytoin, rifampicin) * repeated use of drugs during the last 2 weeks prior to the intended first administration which affect absorption (e.g. laxatives, metoclopramide, loperamide, antacids, H2-receptor antagonists) * known allergic reactions to the active ingredients used or to constituents of the pharmaceutical preparation * subjects with severe allergies or multiple drug allergies